Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010
Mismatch of major vessel obstruction and pulmonary vascular resistance (PVR) in chronic thromboembolic pulmonary hypertension (CTEPH) with associated medical conditions (AMC) Source: Eur Respir J 2006; 28: Suppl. 50, 402s Year: 2006
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Pulmonary artery pressure (PAP) is reduced by inhaled sodium nitroprusside (SNP) in an isolated lung model of pulmonary hypertension: comparison with systemic application Source: Eur Respir J 2002; 20: Suppl. 38, 4s Year: 2002
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003
Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007
Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003
Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH) Source: Eur Respir J 2004; 24: Suppl. 48, 326s Year: 2004
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007
Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2009 - Pulmonary embolism Year: 2009
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005